利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.011 秒)

    ANTI-INFLUENZA VIRUS NEUTRALIZING ANTIBODY
    1.
    发明申请
    ANTI-INFLUENZA VIRUS NEUTRALIZING ANTIBODY 审中-公开
    抗流感病毒中和抗体

    公开(公告)号：US20160200799A1

    公开(公告)日：2016-07-14

    申请号：US14913613

    申请日：2014-08-20

    申请人： FUJITA HEALTH UNIVERSITY ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  PERSEUS PROTEOMICS INC.

    发明人： Yoshikazu KUROSAWA ,  Nobuko OSHIMA ,  Yoshinobu OKUNO ,  Katsuyuki MITOMO ,  Katsushi KOUDA

    IPC分类号： C07K16/10

    CPC分类号： C07K16/1018 ,  C07K2317/76

    摘要： It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).

    摘要翻译： 本发明的目的是提供一种对流感病毒具有高结合活性和高中和活性的新型抗体。 本发明提供中和H1流感病毒和/或H5流感病毒的抗体，其中该抗体具有由定义的重链第一互补决定区（VH CDR1）构成的CDR的重链可变区，定义的重链 第二互补决定区（VH CDR2）和定义的重链第三互补决定区（VH CDR3）和轻链可变区，其具有由定义的轻链第二互补决定区（VL CDR2）和定义的 轻链第三互补决定区（VL CDR3）。

    ANTI-CDH3 HUMANIZED ANTIBODY, DRUG CONJUGATE THEREOF, AND USE THEREOF
    2.
    发明申请
    ANTI-CDH3 HUMANIZED ANTIBODY, DRUG CONJUGATE THEREOF, AND USE THEREOF 有权
    抗CDH3人类抗体，与其结合的药物及其用途

    公开(公告)号：US20160152703A1

    公开(公告)日：2016-06-02

    申请号：US14768151

    申请日：2014-02-14

    申请人： PERSEUS PROTEOMICS INC.

    发明人： Keisuke ISHII ,  Katsuyuki MITOMO ,  Katsushi KOUDA ,  Fumiko NOMURA ,  Yoko KAYUKAWA ,  Tadashi MATSUURA

    IPC分类号： C07K16/28

    CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

    摘要： It is an object of the present invention to produce an anti-CDH3 humanized antibody having lower immunogenicity, and to provide an anti-CDH3 humanized antibody drug conjugate comprising the aforementioned anti-CDH3 humanized antibody that more efficiently kills cancer cells expressing CDH3. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody which comprises complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human κ subgroup I consensus framework sequence or a human germline sequence that is selected under optimal alignment as a framework region sequence of the light chain variable region.

    摘要翻译： 本发明的目的是制备具有较低免疫原性的抗CDH3人源化抗体，并提供包含上述抗CDH3人源化抗体的抗CDH3人源化抗体药物偶联物，其更有效地杀死表达CDH3的癌细胞。 本发明通过将具有细胞毒性的药物与抗CDH3人源化抗体缀合而提供抗CDH3人源化抗体和药物的缀合物，其包含衍生自具有加入细胞的细胞产生的抗体的重链可变区的互补决定区序列 NITE BP-1536，以及衍生自其轻链可变区的互补决定区序列，并且还包含在最佳比对下作为框架区序列选择的重链人亚组III共有框架序列或人种系序列 的重链可变区，以及轻链人和kgr; 亚组I共有框架序列或在最佳比对下选择的人种系序列作为轻链可变区的框架区序列。